Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neurons: The Cell Body and the Dendrites01:23

Neurons: The Cell Body and the Dendrites

6.7K
A typical nerve cell comprises three main components: the cell body, dendrites, and the axon. The cell body, also known as the soma or perikaryon, serves as the central biosynthetic hub housing a nucleus surrounded by cytoplasm containing organelles commonly found in most cells. Notably, Nissl bodies, clusters of the rough endoplasmic reticulum and free ribosomes responsible for protein synthesis, are distinctive features of the neuronal cell body. As neurons age, aggregates of a brown pigment...
6.7K
Vaccinations01:51

Vaccinations

51.3K
Overview
51.3K
What are Cells?01:07

What are Cells?

197.4K
Cells are the smallest and basic units of life, whether it is a single cell that forms the entire organism, e.g., in a bacterium or trillions of them, e.g., in humans. No matter what organism a cell is a part of, they share specific characteristics.
Basic Characteristics of Cells
A living cell has a plasma membrane, a bilayer of lipids that separates the aqueous solution inside the cell called the cytoplasm from the outside environment.
Furthermore, a living cell possesses genetic information...
197.4K
Concentration Cells02:41

Concentration Cells

25.6K
A concentration cell is a type of a  voltaic cell constructed by connecting two almost identical half-cells, both based on the same half-reaction and using the same electrode, differing only in the concentration of one redox species. A concentration cell's potential, therefore, is determined only by the concentration difference of the particular redox species.
Consider the following voltaic cell:
25.6K
What is Cell Signaling?02:03

What is Cell Signaling?

129.9K
Despite the protective membrane that separates a cell from the environment, cells need the ability to detect and respond to environmental changes. Additionally, cells often need to communicate with one another. Unicellular and multicellular organisms use a variety of cell signaling mechanisms to communicate to respond to the environment.
129.9K
Hair Cells01:22

Hair Cells

44.5K
Hair cells are the sensory receptors of the auditory system—they transduce mechanical sound waves into electrical energy that the nervous system can understand. Hair cells are located in the organ of Corti within the cochlea of the inner ear, between the basilar and tectorial membranes. The actual sensory receptors are called inner hair cells. The outer hair cells serve other functions, such as sound amplification in the cochlea, and are not discussed in detail here.
44.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban <i>versus</i> aspirin in JAK2-Positive myeloproliferative neoplasms.

Haematologica·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026
Same author

Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.

The World Allergy Organization journal·2026
Same author

Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.

Journal of the American Academy of Dermatology·2026
Same author

Elevated serum erythropoietin level in JAK2+ polycythemia vera with small vessel Budd-Chiari syndrome.

Blood·2026

Related Experiment Video

Updated: Jan 21, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

12.9K

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.

Amy M Trottier1, Sonia Cerquozzi1, Carolyn J Owen1

  • 1Division of Hematology and Hematological Malignancies, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada, carolyn.owen@ahs.ca.

Blood and Lymphatic Cancer : Targets and Therapy
|July 31, 2019
PubMed
Summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy with poor prognosis. Research identifies CD123 as a therapeutic target, with novel agents like SL-401 showing promise in early studies.

Keywords:
BPDCNcutaneousdendritic cellmyeloidneoplasm

More Related Videos

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.5K
In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System
08:18

In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System

Published on: November 23, 2015

8.9K

Related Experiment Videos

Last Updated: Jan 21, 2026

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow
08:01

Fluorescence-activated Cell Sorting for Purification of Plasmacytoid Dendritic Cells from the Mouse Bone Marrow

Published on: November 4, 2016

12.9K
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
13:34

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors

Published on: March 17, 2014

11.5K
In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System
08:18

In Vitro Generation of Murine Plasmacytoid Dendritic Cells from Common Lymphoid Progenitors using the AC-6 Feeder System

Published on: November 23, 2015

8.9K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive myeloid malignancy.
  • Diagnosis and treatment are challenging, often presenting with nonspecific skin lesions and progressing to leukemia.
  • Current treatment lacks a standard of care, with poor prognosis despite various regimens and stem cell transplantation.

Purpose of the Study:

  • To review the current understanding of BPDCN, including diagnostic and therapeutic challenges.
  • To highlight emerging therapeutic targets and investigational treatments for BPDCN.
  • To emphasize the need for prospective trials to establish optimal treatment strategies.

Main Methods:

  • Review of existing literature on BPDCN.
  • Analysis of mutational landscape and gene expression profiles.
  • Identification of potential therapeutic targets and novel agents.

Main Results:

  • CD123, the IL-3 receptor alpha subunit, is a key therapeutic target in BPDCN.
  • Investigational therapies include SL-401 (a novel agent targeting CD123), UCART123, T-cell immunotherapy, and venetoclax.
  • Limited prospective data exists for current treatment approaches.

Conclusions:

  • BPDCN remains a challenging neoplasm with a poor prognosis.
  • Targeting CD123 with agents like SL-401 represents a promising therapeutic avenue.
  • Prospective clinical trials are essential to determine the most effective treatments for BPDCN.